| Non-Small Cell Lung Carcinoma
Alecensa vs Lumakras
Side-by-side clinical, coverage, and cost comparison for non-small cell lung carcinoma.Deep comparison between: Alecensa vs Lumakras with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsLumakras has a higher rate of injection site reactions vs Alecensa based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Lumakras but not Alecensa, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Alecensa
Lumakras
At A Glance
Oral
Twice daily
ALK/RET tyrosine kinase inhibitor
Oral
Once daily
KRAS G12C inhibitor
Indications
- Non-Small Cell Lung Carcinoma
- Non-Small Cell Lung Carcinoma
- Metastasis from malignant neoplasm of colon and/or rectum
Dosing
Non-Small Cell Lung Carcinoma (adjuvant) 600 mg orally twice daily with food for a total of 2 years or until disease recurrence or unacceptable toxicity following tumor resection of ALK-positive NSCLC (tumors >= 4 cm or node positive).
Non-Small Cell Lung Carcinoma (metastatic) 600 mg orally twice daily with food until disease progression or unacceptable toxicity; reduce to 450 mg orally twice daily for severe hepatic impairment (Child-Pugh C).
Non-Small Cell Lung Carcinoma 960 mg (three 320 mg or four 240 mg or eight 120 mg tablets) orally once daily as a single agent until disease progression or unacceptable toxicity.
Metastasis from malignant neoplasm of colon and/or rectum 960 mg (three 320 mg or four 240 mg or eight 120 mg tablets) orally once daily in combination with panitumumab until disease progression or unacceptable toxicity; administer the first dose prior to the first panitumumab infusion.
Contraindications
—
—
Adverse Reactions
Most common (>=20%) Hepatotoxicity, constipation, fatigue, myalgia, edema, rash, cough
Serious Hepatotoxicity, ILD/pneumonitis, renal impairment, bradycardia, severe myalgia and CPK elevation, hemolytic anemia, pneumonia
Most common (>=20%) - NSCLC Diarrhea, musculoskeletal pain, nausea, fatigue, hepatotoxicity, cough.
Most common (>=20%) - mCRC with panitumumab Rash, dry skin, diarrhea, stomatitis, fatigue, musculoskeletal pain.
Serious Hepatotoxicity, interstitial lung disease/pneumonitis, pneumonia, diarrhea (NSCLC); sepsis, intestinal obstruction (mCRC with panitumumab).
Pharmacology
Alectinib is a tyrosine kinase inhibitor that targets ALK and RET; it inhibits ALK phosphorylation and ALK-mediated activation of downstream signaling proteins STAT3 and AKT, with the major active metabolite M4 showing similar in vitro potency and activity against multiple mutant forms of ALK, including mutations identified in NSCLC tumors that have progressed on crizotinib.
KRAS G12C inhibitor; sotorasib forms an irreversible, covalent bond with the unique cysteine of KRAS G12C, locking the protein in an inactive state that prevents downstream signaling without affecting wild-type KRAS, thereby blocking tumor cell growth and promoting apoptosis in KRAS G12C tumor cell lines.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Alecensa
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (11/12)
Lumakras
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Alecensa
- Covered on 4 commercial plans
- PA (8/8) · Step Therapy (0/8) · Qty limit (8/8)
Lumakras
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (6/8)
Humana
Alecensa
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Lumakras
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAlecensa Access Solutions Bridge Program
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAmgen Safety Net Foundation
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
AlecensaView full Alecensa profile
LumakrasView full Lumakras profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.